ASTRAZENECA P L C MY LATEST STOCK PURCHASE

Yesterday was a good day for the market and a good day for shopping for a new addition to my investment portfolios. I've decided to add shares of drug maker AstraZeneca P L C (AZN:NYSE) to my regular investment portfolio and as a long term holding in my IRA account. AZN has earnings per share of $5.19 with a dividend payout of $3.42, which represents a 7.80% return on their recent share price of $43.94. Their ROE is 35.10% and they have $5.38 per share in cash. They have great profit margins and an acceptable level of debt. As a dividend investment, I'm thinking I will do quite well with AZN.

AstraZeneca PLC is focused on the discover, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. Its primary products include Arimidex for hormonal breast cancer, Crestor that provides treatment for managing cholesterol levels, Nexium for acid-related diseases, Seroquel an atypical anti-psychotic therapy for treating schizophrenia and bipolar mania and Symbicort for the treatment of asthma patients. The company is active in over 100 countries with a growing presence in important emerging markets including China, corporate office in London, UK and major R&D sites in Sweden, the UK and the U.S.. The company owns and operates numerous R&D, production and marketing facilities worldwide. It has over 25 manufacturing sites in over 15 countries. It operates a small number of sites for the manufacture of active ingredients in the UK, Sweden and France, complemented byefficient use of outsourcing.